Answers are grounded in this paper and cite their sources.
This study aimed to compare the clinical characteristics and treatment outcomes of allergic patients (AP) and non-allergic patients (NAP) with severe eosinophilic asthma (SEA) treated with anti-IL5/IL5R biologic agents (mepolizumab, benralizumab, or reslizumab) over one year. Sub-analyses assessed treatment response variations between AP and NAP based on the biological used and compared outcomes among AP with and without fungal allergy.
No takes yet. Share an insight, caveat, or question.
Navarro-Cascales et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: